BRCA1/2 TARGETED MUTATION ANALYSIS (FAMILY MEMBERS)

BRCA1/2 Targeted Mutation Analysis (Family Members) is a specialized molecular genetic test designed to detect a known BRCA1 or BRCA2 gene mutation that has already been identified in a family member. This targeted analysis helps determine whether other biological relatives have inherited the same mutation and may therefore have an increased risk of developing hereditary cancers.

BRCA1 and BRCA2 genes normally help repair damaged DNA and protect against cancer development. Harmful mutations in these genes significantly increase the risk of breast cancer, ovarian cancer, prostate cancer, pancreatic cancer, and certain other hereditary cancers. Testing family members for a known mutation helps identify individuals who may benefit from enhanced cancer screening, preventive measures, and genetic counseling.

Benefits of the Test

• Detects known familial BRCA1 or BRCA2 mutations.
• Assesses inherited cancer risk accurately.
• Supports early cancer surveillance planning.
• Helps guide preventive healthcare decisions.
• Provides valuable information for family members.
• Supports genetic counseling recommendations.
• Facilitates personalized cancer risk management.
• Uses highly accurate molecular genetic testing methods.

Why Doctors Recommend This Test

Doctors recommend this test for biological relatives of individuals who have been diagnosed with a confirmed BRCA1 or BRCA2 mutation. It helps determine whether family members have inherited the same genetic alteration and may be at increased risk for hereditary cancer syndromes.

Early identification of mutation carriers allows healthcare providers to recommend appropriate cancer screening, risk-reduction strategies, and ongoing medical monitoring.

Preparation Before Test

• No fasting is required.
• A blood sample or buccal swab may be collected.
• Provide documentation of the known familial BRCA mutation whenever possible.
• Genetic counseling may be recommended before testing.
• Discuss family medical history with your healthcare provider.
• Follow all sample collection instructions provided by the laboratory.

Normal Reporting Time

Most BRCA1/2 Targeted Mutation Analysis (Family Members) reports at Focus Diagnostics are available within 2–3 hours for specimen processing and molecular workflow initiation. Final genetic analysis and interpretation are generally available within several working days depending on laboratory procedures and quality review requirements.

Who Should Take This Test?

This test may be recommended for:

• First-degree relatives of individuals with BRCA mutations.
• Family members of patients with hereditary breast cancer.
• Relatives of individuals with hereditary ovarian cancer.
• Individuals with a strong family history of BRCA-associated cancers.
• Family members seeking genetic risk assessment.
• People considering preventive cancer screening programs.
• Individuals undergoing genetic counseling.
• Relatives of known BRCA mutation carriers.

Detailed Information

BRCA1 and BRCA2 are tumor suppressor genes that play a critical role in repairing damaged DNA and maintaining genetic stability. When these genes function normally, they help prevent cells from growing uncontrollably. However, inherited mutations can impair this protective function and significantly increase the lifetime risk of developing certain cancers.

Families carrying pathogenic BRCA mutations often demonstrate a pattern of hereditary breast, ovarian, prostate, pancreatic, and related cancers occurring across multiple generations. Once a disease-causing BRCA mutation is identified in one family member, targeted testing can be performed in other biological relatives to determine whether they have inherited the same mutation.

Unlike comprehensive BRCA gene sequencing, targeted mutation analysis focuses specifically on the known familial mutation. This approach is highly accurate, cost-effective, and clinically useful when the disease-causing genetic variant has already been identified in another family member.

A positive result indicates that the individual has inherited the familial BRCA mutation and may have an increased hereditary cancer risk. Such individuals may benefit from enhanced screening protocols, earlier surveillance, preventive interventions, lifestyle modifications, and consultation with oncology and genetics specialists.

A negative result indicates that the tested individual does not carry the known familial mutation. In many cases, this finding may significantly reduce concern regarding the specific hereditary cancer syndrome present in the family, although standard population cancer screening recommendations may still apply.

Genetic counseling is strongly recommended before and after testing to help individuals understand the implications of results, inheritance patterns, risk estimates, and available management options. Family-based genetic testing plays an important role in modern preventive healthcare and precision medicine.

At Focus Diagnostics, BRCA1/2 Targeted Mutation Analysis (Family Members) is performed using advanced molecular genetic technologies, validated testing protocols, and rigorous quality assurance standards to provide accurate, reliable, and clinically meaningful hereditary cancer risk assessment results.